13 Gubin M M, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515: 577-581
[2]
14 Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New Eng J Med, 2014, 371: 2189-2199
[3]
15 Rizvi N A, Hellmann M D, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 2015, 348: 124-128
[4]
16 Sharma P, Allison J P. The future of immune checkpoint therapy. Science, 2015, 348: 56-61
[5]
1 Burnet M. Cancer: A biological approach. I. The processes of control. Br Med J, 1957, 1: 779-786
[6]
2 Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic nude mice. Science, 1974, 183:534-536
[7]
3 Grimm E A, Mazumder A, Rosenberg S A. The human Il-2 induced killer cell phenomenon - lysis of Nk resistant fresh solid tumor-cells by Il-2-activated Pbl. Fed Proc, 1982, 41: 957
[8]
4 McIntyre B W, Allison J P. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum.Cell, 1983, 34: 739-746
[9]
5 Jenkins M K, Schwartz R H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med, 1987, 165: 302-319
[10]
6 Townsend S E, Allison J P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science, 1993,259: 368-370
[11]
7 Linsley P S, Greene J L, Tan P, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med, 1992, 176: 1595-1604
[12]
8 Krummel M F, Allison J P. Cd28 and Ctla-4 have opposing effects on the response of T-cells to stimulation. J Exp Med, 1995, 182:459-465
[13]
9 Walunas T L, Lenschow D J, Bakker C Y, et al. Ctla-4 can function as a negative regulator of T-cell activation. Immunity, 1994, 1:405-413
[14]
10 Leach D R. Krummel M F, Allison J P. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996, 271: 1734-1736
[15]
11 Hodi F S, Lee S, McDermott D F, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. JAMA, 2014, 312: 1744-1753
[16]
12 Eggermont A M, Chiarion-Sileni V, Grob J J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol, 2015, 16: 522-530
